Dosage Forms
- 40 mg and 20 mg enteric coated tablets or capsules.
Drug Group
Proton Pump inhibitor
Packaging
- PVC flacons of 14’s.
Short-term treatment of erosive esophagitis associated with Gastroesophageal Reflux Disease (GERD). Healing and symptomatic relief of erosive esophagitis. Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Suppresses gastric acid secretion by specific inhibition of the hydrogen–potassium ATPase enzyme system at the secretory surface of the gastric parietal cells; blocks the final step of acid production.
Generally, daily treatment with any acid-suppressing medications over a long period of time (eg, longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy.
The followings are the clinical adverse reactions considered possibly: Headache, Diarrhea, Flatulence, Abdominal pain, Rash, Eructation, Insomnia, Hyperglycemia, Nausea, Vomiting, anxiety, arthralgia, asthenia, back pain, bronchitis, chest pain, constipation, cough increased, dizziness, dyspepsia, dyspnea, flu syndrome, gastroenteritis, gastrointestinal disorder, hyperlipidemia, hypertonia, infection, liver function tests abnormal, migraine, neck pain, pain, pharyngitis, rectal disorder, rhinitis, SGPT increased, sinusitis, upper respiratory tract infection, urinary frequency and urinary tract infection.
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Because Pantoprazole is excreted in human milk a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
There have been post marketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including Pantoprazole and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
